PROGRAM OVERVIEW

Effective treatment of MDS requires an individualized, risk-adapted approach. Current strategies for the treatment of MDS, review of ongoing clinical trials and evolving agents for management of MDS will be discussed in this video.

TARGET AUDIENCE

This activity is intended for physicians, oncology nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment and management of patients with Myelodysplastic Syndromes.

LEARNING OBJECTIVES

Upon completion of the educational activity, participants should be able to:

• Interpret findings of key clinical trials that evaluated the use of FDA-approved and novel investigational agents
• Illustrate the pathobiology, clinical presentation, diagnostic evaluation and prognosis of myelodysplastic syndromes

FACULTY & DISCLOSURE

Rami Komrokji, MD
Clinical Director, Associate Professor
Department of Malignant Hematology
H. Lee Moffitt Cancer Center & Research Institute
Tampa, FL

Dr Komrokji has disclosed the following relevant financial relationships:
Advisory Role – Celgene, Novartis